Latest news about IMD Pharma
IMD-Pharma raises 840 k€ from private investors (BAs and WiSEED) to accelerate the development of its assets for the treatment of Rheumatoid Arthritis.
IMD-Pharma signs a joint research agreement with the Inserm research unit U1291 (Infinity, PACID team, Toulouse).
IMD-Pharma validates in vitro and in vivo a new lead for Rheumatoid Arthritis.
IMD-Pharma hires Zakari Mouheb (biology), Laëtitia Lüdge (formulation) and Anthony Augé (chemistry) as apprentices in Master (12 months contract).
IMD-Pharma signs a joint research agreement with the CNRS research unit UMR 5623 (IMRCP, SMODD team, Toulouse).
IMD-Pharma obtains non-dilutive financing from BPI-France to support its growth.
IMD-Pharma hires Dr Emily Clement and Dr Abdelouahd Oukrib as biology and chemistry R&D managers respectively.
IMD-Pharma signs a hosting contract with the Inserm research unit U1291 (Infinity, Toulouse).
IMD-Pharma signs an exclusive licensing agreement with the Toulouse Tech Transfer in human and animal health for 2 new patent families.
IMD-Pharma signs a joint research agreement with Toulouse National Veterinary School (ENVT) and hires Chloé Argoul as an apprentice in Master (bioanalysis, 12 months contract).
IMD-Pharma signs a hosting contract and a joint research agreement with the CNRS research unit UPR 8241 (Laboratoire de Chimie de Coordination, Toulouse).
IMD-Pharma enters NUBBO incubator for a twelve months period.
